Garcinol: Current status of its anti-oxidative, anti-inflammatory and anti-cancer effects

Cancer Letters

Volumn 362, Issue 1, 2015, Pages 8-14

  Liu, Chaoqun ^a,b   Ho, Paul Chi Lui ^b   Wong, Fang Cheng ^a   Sethi, Gautam ^c   Wang, Ling Zhi ^a,c   Goh, Boon Cher ^a,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

Garcinia indica; Garcinol; Pharmacodynamics; Pharmacokinetics; Toxicology

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ANTIOXIDANT; ARACHIDONATE 5 LIPOXYGENASE; CYCLOOXYGENASE 1; GARCINOL; GELATINASE B; MATRILYSIN; PROSTAGLANDIN E2; UNCLASSIFIED DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; TERPENE;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; CELL CYCLE ARREST; CELL GROWTH; CELL PROLIFERATION; DOWN REGULATION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; ENZYME ACTIVATION; GARCINIA; GARCINIA INDICA; GENE EXPRESSION REGULATION; GROWTH INHIBITION; HUMAN; IC50; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY; UPREGULATION; ANIMAL; DRUG SCREENING; METABOLISM; NEOPLASMS;

ANIMALIA; GARCINIA INDICA;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTIOXIDANTS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; NEOPLASMS; TERPENES;

EID: 84931045553     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.03.019     Document Type: Review

References (77)

1. Ramachandran H.D. Plant profile, phytochemistry and pharmacology of garcinia indica: a review. Int. J. Pharm. Sci. Rev. Res 2014, 27(2):376-381.
2. Jayaprakasha G.K., Sakariah K.K. Determination of organic acids in leaves and rinds of Garcinia indica (Desr.) by LC. J. Pharm. Biomed. Anal 2002, 28(2):379-384.
3. Lakshmi C., Kumar K., Dennis T., Kumar T.S.S.P.N.S. Antibacterial activity of polyphenols of Garcinia indica. Indian J. Pharm. Sci 2011, 73(4):470-473.
4. Krishnamurthy N., Lewis Y.S., Ravindranath B. On the structures of garcinol, isogarcinol and camboginol. Tetrahedron Lett 1981, 22(8):793-796.
5. Rama Rao A.V., Venkatswamy G., Pendse D. Camboginol and cambogin. Tetrahedron Lett 1980, 21(20):1975-1978.
6. Padhye S., Ahmad A., Oswal N., Sarkar F.H. Emerging role of Garcinol, the antioxidant chalcone from Garcinia indica Choisy and its synthetic analogs. J. Hematol. Oncol 2009, 2:38.
7. Baliga M.S., Bhat H.P., Pai R.J., Boloor R., Palatty P.L. The chemistry and medicinal uses of the underutilized Indian fruit tree Garcinia indica Choisy (kokum): a review. Food Res. Intern 2011, 44(7):1790-1799.
8. Balasubramanyam K., Altaf M., Varier R.A., Swaminathan V., Ravindran A., Sadhale P.P., et al. Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. J. Biol. Chem 2004, 279(32):33716-33726.
9. Bharate J.B., Vishwakarma R.A., Bharate S.B., Kushwaha M., Gupta A.P. Quantification of anticancer polyisoprenylated benzophenones garcinol and isogarcinol using multiple reaction monitoring Lc-Esi-Ms-Ms in ultra-sound assisted extracts of Garcinia indica fruits. J. Liq. Chromatogr. Relat. Technol 2013, 131231090727009.
10. Sang S., Liao C.-H., Pan M.-H., Rosen R.T., Lin-Shiau S.-Y., Lin J.-K., et al. Chemical studies on antioxidant mechanism of garcinol: analysis of radical reaction products of garcinol with peroxyl radicals and their antitumor activities. Tetrahedron 2002, 58(51):10095-10102.
11. Pandey K.B., Rizvi S.I. Plant polyphenols as dietary antioxidants in human health and disease. Oxid. Med. Cell. Longev 2009, 2(5):270-278.
12. Scalbert A., Johnson I.T., Saltmarsh M. Polyphenols: antioxidants and beyond. Am. J. Clin. Nutr 2005, 81(1):215S-217S.
13. Cooke M.S., Evans M.D., Dizdaroglu M., Lunec J. Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J. 2003, 17(10):1195-1214.
14. Dröge W. Free radicals in the physiological control of cell function. Physiol. Rev 2002, 82(1):47-95.
15. Yamaguchi F., Ariga T., Yoshimura Y., Nakazawa H. Antioxidative and anti-glycation activity of garcinol from garcinia indica fruit rind. J. Agric. Food Chem 2000, 48(2):180-185.
16. Yamaguchi F., Saito M., Ariga T., Yoshimura Y., Nakazawa H. Free radical scavenging activity and antiulcer activity of garcinol from garcinia indica fruit rind. J. Agric. Food Chem 2000, 48(6):2320-2325.
17. Kolodziejczyk J., Masullo M., Olas B., Piacente S., Wachowicz B. Effects of garcinol and guttiferone K isolated from Garcinia cambogia on oxidative/nitrative modifications in blood platelets and plasma. Platelets 2009, 20(7):487-492.
18. Calabrese V., Boyd-Kimball D., Scapagnini G., Butterfield D.A. Nitric oxide and cellular stress response in brain aging and neurodegenerative disorders: the role of vitagenes. In Vivo 2004, 18(3):245-268.
19. Liao C.H., Sang S., Liang Y.C., Ho C.T., Lin J.K. Suppression of inducible nitric oxide synthase and cyclooxygenase-2 in downregulating nuclear factor-kappa B pathway by Garcinol. Mol. Carcinog 2004, 41(3):140-149.
20. Cattell V., Jansen A. Inducible nitric oxide synthase in inflammation. Histochem. J. 1995, 27(10):777-784.
21. Zarubin T., Han J. Activation and signaling of the p38 MAP kinase pathway. Cell Res 2005, 15(1):11-18.
22. Kim S.Y., Kim T.-B., Moon K.-A., Kim T.J., Shin D., Cho Y.S., et al. Regulation of pro-inflammatory responses by lipoxygenases via intracellular reactive oxygen species in vitro and in vivo. Exp. Mol. Med 2008, 40:461-476.
23. Hong J., Sang S., Park H.J., Kwon S.J., Suh N., Huang M.T., et al. Modulation of arachidonic acid metabolism and nitric oxide synthesis by garcinol and its derivatives. Carcinogenesis 2006, 27(2):278-286.
24. Koeberle A., Northoff H., Werz O. Identification of 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 as functional targets of the anti-inflammatory and anti-carcinogenic garcinol. Biochem. Pharmacol 2009, 77(9):1513-1521.
25. Rakoff-Nahoum S. Why cancer and inflammation?. Yale J. Biol. Med 2006, 79(3-4):123-130.
26. Ahmad A., Wang Z., Ali R., Maitah M.Y., Kong D., Banerjee S., et al. Apoptosis-inducing effect of garcinol is mediated by NF-kappaB signaling in breast cancer cells. J. Cell. Biochem 2010, 109(6):1134-1141.
27. Ahmad A., Sarkar S.H., Bitar B., Ali S., Aboukameel A., Sethi S., et al. Garcinol regulates EMT and wnt signaling pathways in vitro and in vivo, leading to anticancer activity against breast cancer cells. Mol. Cancer Ther 2012, 11(10):2193-2201.
28. Collins H.M., Abdelghany M.K., Messmer M., Yue B., Deeves S.E., Kindle K.B., et al. Differential effects of garcinol and curcumin on histone and p53 modifications in tumour cells. BMC Cancer 2013, 13:37.
29. Chen C.S., Lee C.H., Hsieh C.D., Ho C.T., Pan M.H., Huang C.S., et al. Nicotine-induced human breast cancer cell proliferation attenuated by garcinol through down-regulation of the nicotinic receptor and cyclin D3 proteins. Breast Cancer Res. Treat 2011, 125(1):73-87.
30. Hong J., Kwon S.J., Sang S., Ju J., Zhou J.N., Ho C.T., et al. Effects of garcinol and its derivatives on intestinal cell growth: inhibitory effects and autoxidation-dependent growth-stimulatory effects. Free Rad. Biol. Med 2007, 42(8):1211-1221.
31. Liao C.H., Sang S., Ho C.T., Lin J.K. Garcinol modulates tyrosine phosphorylation of FAK and subsequently induces apoptosis through down-regulation of Src, ERK, and Akt survival signaling in human colon cancer cells. J. Cell. Biochem 2005, 96(1):155-169.
32. Tsai M.-L., Chiou Y.-S., Chiou L.-Y., Ho C.-T., Pan M.-H. Garcinol suppresses inflammation-associated colon carcinogenesis in mice. Mol. Nutr. Food Res 2014, 1613-4133. Electronic.
33. Tanaka T., Kohno H., Shimada R., Kagami S., Yamaguchi F., Kataoka S., et al. Prevention of colonic aberrant crypt foci by dietary feeding of garcinol in male F344 rats. Carcinogenesis 2000, 21(6):1183-1189.
34. Prasad S., Ravindran J., Sung B., Pandey M.K., Aggarwal B.B. Garcinol potentiates TRAIL-induced apoptosis through modulation of death receptors and antiapoptotic proteins. Mol. Cancer Ther 2010, 9(4):856-868.
35. Matsumoto K., Akao Y., Kobayashi E., Ito T., Ohguchi K., Tanaka T., et al. Cytotoxic benzophenone derivatives from garcinia species display a strong apoptosis-inducing effect against human leukemia cell lines. Biol. Pharm. Bull 2003, 26(4):569-571.
36. Pan M.-H., Chang W.-L., Lin-Shiau S.-Y., Ho C.-T., Lin J.-K. Induction of apoptosis by garcinol and curcumin through cytochrome c release and activation of caspases in human leukemia HL-60 cells. J. Agric. Food Chem 2001, 49(3):1464-1474.
37. Cheng A.C., Tsai M.L., Liu C.M., Lee M.F., Nagabhushanam K., Ho C.T., et al. Garcinol inhibits cell growth in hepatocellular carcinoma Hep3B cells through induction of ROS-dependent apoptosis. Food Funct 2010, 1(3):301-307.
38. Sethi G., Chatterjee S., Rajendran P., Li F., Shanmugam M.K., Wong K.F., et al. Inhibition of STAT3 dimerization and acetylation by garcinol suppresses the growth of human hepatocellular carcinoma in vitro and in vivo. Mol. Cancer 2014, 13:66.
39. Yu S.Y., Liao C.H., Chien M.H., Tsai T.Y., Lin J.K., Weng M.S. Induction of p21(Waf1/Cip1) by garcinol via downregulation of p38-MAPK signaling in p53-independent H1299 lung cancer. J. Agric. Food Chem 2014, 62(9):2085-2095.
40. Oike T., Ogiwara H., Torikai K., Nakano T., Yokota J., Kohno T. Garcinol, a histone acetyltransferase inhibitor, radiosensitizes cancer cells by inhibiting non-homologous end joining. Int. J. Radiat. Oncol. Biol. Phys 2012, 84(3):815-821.
41. Parasramka M.A., Gupta S.V. Garcinol inhibits cell proliferation and promotes apoptosis in pancreatic adenocarcinoma cells. Nutr. Cancer 2011, 63(3):456-465.
42. Parasramka M.A., Gupta S.V. Synergistic effect of garcinol and curcumin on antiproliferative and apoptotic activity in pancreatic cancer cells. J. Oncol 2012, 2012:709739.
43. Parasramka M.A., Ali S., Banerjee S., Deryavoush T., Sarkar F.H., Gupta S. Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures. Mol. Nutr. Food Res 2013, 57(2):235-248.
44. Ahmad A., Sarkar S.H., Aboukameel A., Ali S., Biersack B., Seibt S., et al. Anticancer action of garcinol in vitro and in vivo is in part mediated through inhibition of STAT-3 signaling. Carcinogenesis 2012, 33(12):2450-2456.
45. Chen X., Zhang X., Lu Y., Shim J.-Y., Sang S., Sun Z., et al. Chemoprevention of 7,12-dimethylbenz[a]anthracene (DMBA)-induced hamster cheek pouch carcinogenesis by a 5-Lipoxygenase inhibitor, garcinol. Nutr. Cancer 2012, 64(8):1211-1218.
46. Yoshida K., Tanaka T., Hirose Y., Yamaguchi F., Kohno H., Toida M., et al. Dietary garcinol inhibits 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in rats. Cancer Lett 2005, 221(1):29-39.
47. Li F., Shanmugam M.K., Chen L., Chatterjee S., Basha J., Kumar A.P., et al. Garcinol, a polyisoprenylated benzophenone modulates multiple proinflammatory signaling cascades leading to the suppression of growth and survival of head and neck carcinoma. Cancer Prevention Research 2013, 6(8):843-854.
48. Knab L.M., Grippo P.J., Bentrem D.J. Involvement of eicosanoids in the pathogenesis of pancreatic cancer: the roles of cyclooxygenase-2 and 5-lipoxygenase. World J. Gastroenterol 2014, 20(31):10729-10739.
49. Brown J.R., DuBois R.N. Cyclooxygenase as a target in lung cancer. Clin. Cancer Res 2004, 10(12):4266s-4269s.
50. Kondo M., Hla T. Expression of Cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995, 55(17):3785-3789.
51. Xiong S., Mu T., Wang G., Jiang X. Mitochondria-mediated apoptosis in mammals. Protein Cell 2014, 5(10):737-749.
52. Hoesel B., Schmid J. The complexity of NF-kappaB signaling in inflammation and cancer. Mol. Cancer 2013, 12(1):86.
53. Biswas D.K., Shi Q., Baily S., Strickland I., Ghosh S., Pardee A.B., et al. NF-κB activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc. Natl. Acad. Sci. U.S.A. 2004, 101(27):10137-10142.
54. Collins I., Garrett M.D. Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Curr. Opin. Pharmacol 2005, 5(4):366-373.
55. Cicenas J., Valius M. The CDK inhibitors in cancer research and therapy. J. Cancer Res. Clin. Oncol 2011, 137(10):1409-1418.
56. Manzo F., Tambaro F.P., Mai A., Altucci L. Histone acetyltransferase inhibitors and preclinical studies. Expert Opin. Ther. Pat 2009, 19(6):761-774.
57. Bergers G., Brekken R., McMahon G., Vu T.H., Itoh T., Tamaki K., et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol 2000, 2(10):737-744.
58. Borrow J., Stanton V.P., Andresen J.M., Becher R., Behm F.G., Chaganti R.S.K., et al. The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat. Genet 1996, 14(1):33-41.
59. Lynam-Lennon N., Maher S.G., Reynolds J.V. The roles of microRNA in cancer and apoptosis. Biol. Rev. Camb. Philos. Soc 2009, 84(1):55-71.
60. Zhao Y., Deng C., Wang J., Xiao J., Gatalica Z., Recker R., et al. Let-7 family miRNAs regulate estrogen receptor alpha signaling in estrogen receptor positive breast cancer. Breast Cancer Res. Treat 2011, 127(1):69-80.
61. Zhang B., Pan X., Cobb G.P., Anderson T.A. MicroRNAs as oncogenes and tumor suppressors. Dev. Biol 2007, 302(1):1-12.
62. Sicard F., Gayral M., Lulka H., Buscail L., Cordelier P. Targeting miR-21 for the therapy of pancreatic cancer. Mol. Ther 2013, 21(5):986-994.
63. Asangani I.A., Rasheed S.A.K., Nikolova D.A., Leupold J.H., Colburn N.H., Post S., et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2007, 27(15):2128-2136.
64. Coussens L.M., Fingleton B., Matrisian L.M. Matrix metalloproteinase inhibitors and cancer - trials and tribulations. Science 2002, 295(5564):2387-2392.
65. Rapisarda A., Melillo G. Role of the VEGF/VEGFR axis in cancer biology and therapy. Advances in Cancer Research 2012, vol. 114:237-267. Academic Press.
66. Koskensalo S., Louhimo J., Nordling S., Hagström J., Haglund C. MMP-7 as a prognostic marker in colorectal cancer. Tumor Biol 2011, 32(2):259-264.
67. Qin C., Tan K.L., Zhang C.L., Tan C.Y., Chen Y.Z., Jiang Y.Y. What does it take to synergistically combine sub-potent natural products into drug-level potent combinations?. PLoS ONE 2012, 7(11):e49969.
68. Gupta C., Prakash D. Phytonutrients as therapeutic agents. J. Complement. Integr. Med 2014, 11:151.
69. Frank D.A. STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett 2007, 251(2):199-210.
70. Kumar S.V., Saravanan D., Kumar B., Jayakumar A. An update on prodrugs from natural products. Asian Pac. J. Trop. Med 2014, 7(Suppl. 1 (0)):S54-S59.
71. Mathijssen R.H.J., van Alphen R.J., Verweij J., Loos W.J., Nooter K., Stoter G., et al. Clinical pharmacokinetics and metabolism of Irinotecan (CPT-11). Clin. Cancer Res 2001, 7(8):2182-2194.
72. US Food and Drug Administration Bioavailability and bioequivalence studies for orally administered drug products - general considerations. US Department of Health and Human Services CaC, e. R., MD 2003., Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations 2003, Rockville, MD. US Department of Health and Human Services, C. a. C. (Ed.).
73. Yang K.Y., Lin L.C., Tseng T.Y., Wang S.C., Tsai T.H. Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC-MS/MS. J. Chromatogr. B 2007, 853(1-2):183-189.
74. Anand P., Kunnumakkara A.B., Newman R.A., Aggarwal B.B. Bioavailability of curcumin: problems and promises. Mol. Pharm 2007, 4(6):807-818.
75. Li L., Brunner I., Han A.-R., Hamburger M., Kinghorn A.D., Frye R., et al. Pharmacokinetics of α-mangostin in rats after intravenous and oral application. Mol. Nutr. Food Res 2011, 55(S1):S67-S74.
76. Calixto J.B. Efficacy, safety, quality control, marketing and regulatory guidelines for herbal medicines (phytotherapeutic agents). Braz. J. Med. Biol. Res 2000, 33:179-189.
77. Heinrich M., Lee Teoh H. Galanthamine from snowdrop - the development of a modern drug against Alzheimer's disease from local Caucasian knowledge. J. Ethnopharmacol 2004, 92(2-3):147-162.